Holen Sie sich die Stockscreener-App
11.69
5.65%
-0.70
Handel nachbörslich:
11.92
0.23
+1.97%
Schlusskurs vom Vortag:
$12.39
Offen:
$12.34
24-Stunden-Volumen:
3.54M
Relative Volume:
1.04
Marktkapitalisierung:
$1.57B
Einnahmen:
$24.30M
Nettoeinkommen (Verlust:
$-145.57M
KGV:
-8.7895
EPS:
-1.33
Netto-Cashflow:
$-149.17M
1W Leistung:
+5.74%
1M Leistung:
+28.18%
6M Leistung:
+97.80%
1J Leistung:
+325.09%
1-Tages-Spanne:
$11.59
$12.62
1-Wochen-Bereich:
$9.99
$12.62
52-Wochen-Spanne:
$1.03
$12.62
Tango Therapeutics Inc Stock (TNGX) Company Profile
Firmenname
Tango Therapeutics Inc
Sektor
Branche
Telefon
(857) 320-4900
Adresse
201 BROOKLINE AVENUE, BOSTON
Vergleichen Sie TNGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
11.69 | 1.67B | 24.30M | -145.57M | -149.17M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.92 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.92 | 79.26B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.24 | 49.47B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.26 | 48.47B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.29 | 38.37B | 4.98B | 69.59M | 525.67M | 0.5197 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-08 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten
Tango Therapeutics (NASDAQ:TNGX) Sets New 52-Week HighHere's Why - MarketBeat
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Nasdaq Futures Research-Driven Model - Kalkine Media
TNGX: Leadership shift supports late-stage trials and robust MTAP-deleted cancer pipeline progress - TradingView — Track All Markets
Tango Therapeutics (NASDAQ:TNGX) Trading 8.3% HigherShould You Buy? - MarketBeat
TNGX: Smooth leadership transition supports late-stage trials in MTAP-deleted cancers and robust 2026 milestones - TradingView — Track All Markets
Sentiment Review: Will Tango Therapeutics Inc stock recover after earningsEntry Point & Intraday High Probability Alerts - baoquankhu1.vn
Tango Therapeutics (NASDAQ:TNGX) Stock Price Down 8.4%What's Next? - MarketBeat
Tango Therapeutics stock maintains Buy rating at Stifel on encouraging early data - Investing.com Canada
Tango Therapeutics stock maintains Buy rating at Stifel on encouraging early data By Investing.com - Investing.com India
Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 29% - 富途牛牛
Does Tango Therapeutics’ (TNGX) CEO Transition Clarify or Complicate Its Precision Oncology Roadmap? - Yahoo Finance
Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor - Sahm
Can Tango Therapeutics Inc. stock sustain market leadershipJuly 2025 Macro Moves & Weekly Return Optimization Plans - Улправда
How Tango Therapeutics Inc. stock reacts to oil prices2025 Institutional Moves & Stock Timing and Entry Methods - Улправда
Tango Therapeutics Appoints Dr. Malte Peters as CEO - citybiz
Can Tango Therapeutics Inc. stock resist market sell offsJuly 2025 Macro Moves & Safe Capital Growth Plans - Улправда
Will Tango Therapeutics Inc. stock deliver long term returnsTrade Exit Summary & Daily Price Action Insights - Улправда
Tango Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective January 8, 2026 - marketscreener.com
Tango Therapeutics' CEO Retires, Successor Appointed; Shares Fall - MarketScreener
Is Tango Therapeutics Inc. stock a defensive play in 2025Dip Buying & Short-Term High Return Ideas - Улправда
Tango Therapeutics announces CEO transition: Barbara Weber to retire, Malte Peters appointed successor - marketscreener.com
Tango Therapeutics appoints Malte Peters as new CEO By Investing.com - Investing.com Australia
Tango Therapeutics appoints new CEO amid leadership transition - TipRanks
Tango Therapeutics appoints Malte Peters as new CEO - Investing.com
Tango Therapeutics Announces Leadership Transition: Barbara Weber, M.D. Becomes Executive Chair as Malte Peters, M.D. Assumes Role of President and CEO - Quiver Quantitative
Tango Therapeutics stock hits 52-week high at $11.21 By Investing.com - Investing.com Nigeria
Tango Therapeutics (NASDAQ:TNGX) Sets New 12-Month HighHere's What Happened - MarketBeat
Tango Therapeutics stock hits 52-week high at $11.21 - Investing.com India
Tango Therapeutics (NASDAQ:TNGX) Trading Up 8.4%Here's What Happened - MarketBeat
Tango Therapeutics appoints Sung Lee to board of directors By Investing.com - Investing.com Nigeria
Tango Therapeutics adds independent director to strengthen governance - MSN
Tango Therapeutics Adds Independent Director to Strengthen Governance - TipRanks
Tango Therapeutics appoints Sung Lee to board of directors - Investing.com
Tango Therapeutics Appoints Sung Lee to Board of Directors - The Manila Times
Hindware Home Innovation Limited Reaches Critical Trendline SupportStraddle and Strangle Trades & Low Risk Investment Plans - earlytimes.in
Tango Therapeutics (NASDAQ:TNGX) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Nasdaq index Notes Liquidity Move - Kalkine Media
Tango Therapeutics Advances TNG462 Study for MTAP-deleted Tumors - MSN
Patterns Watch: How Tango Therapeutics Inc stock reacts to oil pricesDip Buying & Safe Entry Point Identification - moha.gov.vn
Tango Therapeutics (TNGX) Upgraded to Buy: Here's Why - MSN
3 Stocks With Strong Upside Potential for 2026 Gains - Tokenist
Biotech Stocks: Jefferies Names its 6 Top Picks for 2026 - Investing.com
Certain Common Stock of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2025. - marketscreener.com
Certain Pre-Funded Warrants of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2025. - marketscreener.com
3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 - WV News
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is Tango Therapeutics Inc. stock a smart buy before Fed meetingJuly 2025 Sentiment & Fast Entry High Yield Tips - Улправда
Will Tango Therapeutics Inc. stock benefit from commodity pricesJuly 2025 Trends & AI Driven Stock Reports - Улправда
Why Tango Therapeutics Inc. stock remains a top recommendationMarket Trend Report & Technical Pattern Based Signals - DonanımHaber
Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
1.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):